Company profile
Protagonist Therapeutics, Inc
NASDAQ:PTGXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Rusfertide | phase2 | — | 6 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05210790 | phase3 | active_not_recruiting | 2022-04-01 | 2025-02-21 | Protagonist Therapeutics, Inc. | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera |
| NCT04057040 | phase2 | completed | 2019-10-01 | 2023-02-14 | Protagonist Therapeutics, Inc. | Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) |
| NCT04504383 | phase2 | completed | 2020-08-05 | 2023-02-16 | Protagonist Therapeutics, Inc. | PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC) |
| NCT04767802 | phase2 | completed | 2021-02-02 | 2023-03-15 | Protagonist Therapeutics, Inc. | PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit |
| NCT04202965 | phase2 | completed | 2020-03-19 | 2021-10-06 | Protagonist Therapeutics, Inc. | PTG-300 in Subjects With Hereditary Hemochromatosis |
FDA applications (0)
No records yet.